PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. (2017)
Attributed to:
King's Health Partners Confidence in Concept
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13058-016-0789-y
PubMed Identifier: 28095868
Publication URI: http://europepmc.org/abstract/MED/28095868
Type: Journal Article/Review
Volume: 19
Parent Publication: Breast cancer research : BCR
Issue: 1
ISSN: 1465-5411